Research ArticleArticle
Open Access
Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review
Puja Mehta, Sebastian E. Sattui, Kornelis S.M. van der Geest, Elisabeth Brouwer, Richard Conway, Michael S. Putman, Philip C. Robinson and Sarah L. Mackie
The Journal of Rheumatology October 2020, jrheum.200766; DOI: https://doi.org/10.3899/jrheum.200766
Puja Mehta
PM is a clinical training fellow within the Medical Research Council— GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this work. PM also receives cofunding from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MP is supported in part by Grant Number T32 AR007611-13 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). SES received funding from the Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and NIAMS (U54 AR057319). SLM receives infrastructure support from the MRC TARGET Partnership Grant (MR/N011775/1/MRC_/Medical Research Council/United Kingdom) and from the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK; S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA; P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia; S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. P. Mehta, S.E. Sattui, and K. van der Geest made equal contributions to this work. KSMvdG received a speaker fee from Roche (2019) paid to the UMCG. EB received consultancy and speaker fees from Roche (2017 and 2018) paid to the UMCG. PR reports no competing interests related to this work, outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche. SLM received consultancy fees from Roche (2015) and was supported by Roche to attend EULAR 2019. She has acted as investigator on clinical trials in GCA for Sanofi, Roche and GSK. Consultancy fees from Roche (2016, 2018) and Sanofi (2017) were paid to her institution. She is Patron of the UK charity Polymyalgia Rheumatica & Giant Cell Arteritis UK. RC, PM, MSP, SES have no conflicts of interest declared. Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Harrogate Road, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 29, 2020.
Sebastian E. Sattui
PM is a clinical training fellow within the Medical Research Council— GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this work. PM also receives cofunding from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MP is supported in part by Grant Number T32 AR007611-13 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). SES received funding from the Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and NIAMS (U54 AR057319). SLM receives infrastructure support from the MRC TARGET Partnership Grant (MR/N011775/1/MRC_/Medical Research Council/United Kingdom) and from the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK; S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA; P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia; S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. P. Mehta, S.E. Sattui, and K. van der Geest made equal contributions to this work. KSMvdG received a speaker fee from Roche (2019) paid to the UMCG. EB received consultancy and speaker fees from Roche (2017 and 2018) paid to the UMCG. PR reports no competing interests related to this work, outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche. SLM received consultancy fees from Roche (2015) and was supported by Roche to attend EULAR 2019. She has acted as investigator on clinical trials in GCA for Sanofi, Roche and GSK. Consultancy fees from Roche (2016, 2018) and Sanofi (2017) were paid to her institution. She is Patron of the UK charity Polymyalgia Rheumatica & Giant Cell Arteritis UK. RC, PM, MSP, SES have no conflicts of interest declared. Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Harrogate Road, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 29, 2020.
Kornelis S.M. van der Geest
PM is a clinical training fellow within the Medical Research Council— GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this work. PM also receives cofunding from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MP is supported in part by Grant Number T32 AR007611-13 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). SES received funding from the Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and NIAMS (U54 AR057319). SLM receives infrastructure support from the MRC TARGET Partnership Grant (MR/N011775/1/MRC_/Medical Research Council/United Kingdom) and from the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK; S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA; P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia; S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. P. Mehta, S.E. Sattui, and K. van der Geest made equal contributions to this work. KSMvdG received a speaker fee from Roche (2019) paid to the UMCG. EB received consultancy and speaker fees from Roche (2017 and 2018) paid to the UMCG. PR reports no competing interests related to this work, outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche. SLM received consultancy fees from Roche (2015) and was supported by Roche to attend EULAR 2019. She has acted as investigator on clinical trials in GCA for Sanofi, Roche and GSK. Consultancy fees from Roche (2016, 2018) and Sanofi (2017) were paid to her institution. She is Patron of the UK charity Polymyalgia Rheumatica & Giant Cell Arteritis UK. RC, PM, MSP, SES have no conflicts of interest declared. Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Harrogate Road, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 29, 2020.
Elisabeth Brouwer
PM is a clinical training fellow within the Medical Research Council— GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this work. PM also receives cofunding from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MP is supported in part by Grant Number T32 AR007611-13 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). SES received funding from the Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and NIAMS (U54 AR057319). SLM receives infrastructure support from the MRC TARGET Partnership Grant (MR/N011775/1/MRC_/Medical Research Council/United Kingdom) and from the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK; S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA; P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia; S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. P. Mehta, S.E. Sattui, and K. van der Geest made equal contributions to this work. KSMvdG received a speaker fee from Roche (2019) paid to the UMCG. EB received consultancy and speaker fees from Roche (2017 and 2018) paid to the UMCG. PR reports no competing interests related to this work, outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche. SLM received consultancy fees from Roche (2015) and was supported by Roche to attend EULAR 2019. She has acted as investigator on clinical trials in GCA for Sanofi, Roche and GSK. Consultancy fees from Roche (2016, 2018) and Sanofi (2017) were paid to her institution. She is Patron of the UK charity Polymyalgia Rheumatica & Giant Cell Arteritis UK. RC, PM, MSP, SES have no conflicts of interest declared. Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Harrogate Road, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 29, 2020.
Richard Conway
PM is a clinical training fellow within the Medical Research Council— GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this work. PM also receives cofunding from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MP is supported in part by Grant Number T32 AR007611-13 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). SES received funding from the Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and NIAMS (U54 AR057319). SLM receives infrastructure support from the MRC TARGET Partnership Grant (MR/N011775/1/MRC_/Medical Research Council/United Kingdom) and from the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK; S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA; P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia; S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. P. Mehta, S.E. Sattui, and K. van der Geest made equal contributions to this work. KSMvdG received a speaker fee from Roche (2019) paid to the UMCG. EB received consultancy and speaker fees from Roche (2017 and 2018) paid to the UMCG. PR reports no competing interests related to this work, outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche. SLM received consultancy fees from Roche (2015) and was supported by Roche to attend EULAR 2019. She has acted as investigator on clinical trials in GCA for Sanofi, Roche and GSK. Consultancy fees from Roche (2016, 2018) and Sanofi (2017) were paid to her institution. She is Patron of the UK charity Polymyalgia Rheumatica & Giant Cell Arteritis UK. RC, PM, MSP, SES have no conflicts of interest declared. Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Harrogate Road, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 29, 2020.
Michael S. Putman
PM is a clinical training fellow within the Medical Research Council— GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this work. PM also receives cofunding from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MP is supported in part by Grant Number T32 AR007611-13 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). SES received funding from the Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and NIAMS (U54 AR057319). SLM receives infrastructure support from the MRC TARGET Partnership Grant (MR/N011775/1/MRC_/Medical Research Council/United Kingdom) and from the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK; S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA; P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia; S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. P. Mehta, S.E. Sattui, and K. van der Geest made equal contributions to this work. KSMvdG received a speaker fee from Roche (2019) paid to the UMCG. EB received consultancy and speaker fees from Roche (2017 and 2018) paid to the UMCG. PR reports no competing interests related to this work, outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche. SLM received consultancy fees from Roche (2015) and was supported by Roche to attend EULAR 2019. She has acted as investigator on clinical trials in GCA for Sanofi, Roche and GSK. Consultancy fees from Roche (2016, 2018) and Sanofi (2017) were paid to her institution. She is Patron of the UK charity Polymyalgia Rheumatica & Giant Cell Arteritis UK. RC, PM, MSP, SES have no conflicts of interest declared. Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Harrogate Road, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 29, 2020.
Philip C. Robinson
PM is a clinical training fellow within the Medical Research Council— GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this work. PM also receives cofunding from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MP is supported in part by Grant Number T32 AR007611-13 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). SES received funding from the Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and NIAMS (U54 AR057319). SLM receives infrastructure support from the MRC TARGET Partnership Grant (MR/N011775/1/MRC_/Medical Research Council/United Kingdom) and from the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK; S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA; P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia; S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. P. Mehta, S.E. Sattui, and K. van der Geest made equal contributions to this work. KSMvdG received a speaker fee from Roche (2019) paid to the UMCG. EB received consultancy and speaker fees from Roche (2017 and 2018) paid to the UMCG. PR reports no competing interests related to this work, outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche. SLM received consultancy fees from Roche (2015) and was supported by Roche to attend EULAR 2019. She has acted as investigator on clinical trials in GCA for Sanofi, Roche and GSK. Consultancy fees from Roche (2016, 2018) and Sanofi (2017) were paid to her institution. She is Patron of the UK charity Polymyalgia Rheumatica & Giant Cell Arteritis UK. RC, PM, MSP, SES have no conflicts of interest declared. Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Harrogate Road, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 29, 2020.
Sarah L. Mackie
PM is a clinical training fellow within the Medical Research Council— GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this work. PM also receives cofunding from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MP is supported in part by Grant Number T32 AR007611-13 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). SES received funding from the Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and NIAMS (U54 AR057319). SLM receives infrastructure support from the MRC TARGET Partnership Grant (MR/N011775/1/MRC_/Medical Research Council/United Kingdom) and from the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. P. Mehta, Rheumatology Fellow, MD, Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, Department of Rheumatology, University College London Hospital (UCLH) NHS Trust, London, UK; S.E. Sattui, Rheumatology Fellow, MD, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; K. van der Geest, Rheumatology Fellow, PhD, E. Brouwer, Internist Rheumatologist, Associate Professor, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; R. Conway, Consultant Rheumatologist, PhD, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; M.S. Putman, Clinical Instructor of Medicine, MD, Division of Rheumatology, Department of Medicine, Northwestern University, Chicago, IL, USA; P. Robinson, Associate Professor, PhD, University of Queensland Faculty of Medicine, Brisbane, Australia; S.L. Mackie, Associate Clinical Professor and Honorary Consultant Rheumatologist, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. P. Mehta, S.E. Sattui, and K. van der Geest made equal contributions to this work. KSMvdG received a speaker fee from Roche (2019) paid to the UMCG. EB received consultancy and speaker fees from Roche (2017 and 2018) paid to the UMCG. PR reports no competing interests related to this work, outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB and travel assistance from Roche. SLM received consultancy fees from Roche (2015) and was supported by Roche to attend EULAR 2019. She has acted as investigator on clinical trials in GCA for Sanofi, Roche and GSK. Consultancy fees from Roche (2016, 2018) and Sanofi (2017) were paid to her institution. She is Patron of the UK charity Polymyalgia Rheumatica & Giant Cell Arteritis UK. RC, PM, MSP, SES have no conflicts of interest declared. Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Harrogate Road, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 29, 2020.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review
Puja Mehta, Sebastian E. Sattui, Kornelis S.M. van der Geest, Elisabeth Brouwer, Richard Conway, Michael S. Putman, Philip C. Robinson, Sarah L. Mackie
The Journal of Rheumatology Oct 2020, jrheum.200766; DOI: 10.3899/jrheum.200766
Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review
Puja Mehta, Sebastian E. Sattui, Kornelis S.M. van der Geest, Elisabeth Brouwer, Richard Conway, Michael S. Putman, Philip C. Robinson, Sarah L. Mackie
The Journal of Rheumatology Oct 2020, jrheum.200766; DOI: 10.3899/jrheum.200766